China SXT Pharmaceuticals-ASXTC
13F holders, Q3 2024 (September 30)7holders
3new positions
3sold out
$0.64avg. 13F price*
At the end of Q3 2024, 7 institutions reported holding China SXT Pharmaceuticals-A (SXTC) in their 13F filings, unchanged from Q2 2024. 3 opened new positions and 3 sold out. The largest holders were Gsa Capital Partners LLP ($9K), Baader Bank Aktiengesellschaft ($8K) and Bank of Montreal ($6K).
- Company
- China SXT Pharmaceuticals-A
- CUSIP
- G2161P140
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $17K |
| Exits | 3 | $52K |
All 13F filers, Q2 2024 → Q3 2024: 27,837 shares bought and 54,302 shares sold, net −26,465 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Gsa Capital Partners LLP | 0.00% | New | 12,300 | $9K |
| Baader Bank Aktiengesellschaft | 0.00% | New | 15,161 | $8K |
| Bank of Montreal | 0.00% | No change | 10,000 | $6K |
| UBS Group AG | 0.00% | Reduce -31.0% | 8,678 | $6K |
| JPMorgan Chase & Co. | 0.00% | New | 376 | $274 |
| Acadian Asset Management LLC | 0.00% | Reduce -86.3% | 379 | $0 |
| Banque Cantonale Vaudoise | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is SXTC's weight in each manager's 13F, not the share of China SXT Pharmaceuticals-A the manager owns.